Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 66,000 shares, a decrease of 44.8% from the October 15th total of 119,500 shares. Based on an average daily volume of 130,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are short sold.

Bolt Biotherapeutics Stock Up 1.3 %

NASDAQ BOLT traded up $0.01 on Wednesday, hitting $0.65. 18,856 shares of the stock traded hands, compared to its average volume of 165,183. The stock has a 50-day moving average of $0.64 and a 200 day moving average of $0.74. Bolt Biotherapeutics has a twelve month low of $0.55 and a twelve month high of $1.56. The company has a market capitalization of $24.87 million, a P/E ratio of -0.37 and a beta of 0.92. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.19.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 592.57% and a negative return on equity of 61.40%. The business had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.02 million. As a group, analysts expect that Bolt Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bolt Biotherapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.50.

Institutional Investors Weigh In On Bolt Biotherapeutics

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. bought a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned 0.09% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 86.70% of the stock is owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.